Overview of Iloprost

Property	Description
Active Ingredient	Iloprost (typically as the trometamol salt)
Forms	Solution for Inhalation (nebulizer) and IV Infusion
Pharmacological Class	Prostacyclin Analog (or Vasodilator)
Origin	Synthetic (chemically stable derivative of natural PGI2)
Mechanism Principle	Widens blood vessels and mildly prevents platelet stickiness

What Type of Medicine is Iloprost?

Iloprost is the active, synthetic ingredient belonging to the Prostacyclin Analog pharmacological class, designed to mimic a naturally occurring hormone in the body called prostacyclin (PGI2). This reflects its role as a powerful vasodilator. This means the medicine works like one of the body’s own powerful blood vessel relaxers to improve circulation.

Differentiation and Recognition: Iloprost possesses a key advantage over natural prostacyclin: it is a chemically stable derivative with a longer half-life, a property that makes effective therapeutic use possible. Iloprost is recognized for its ability to improve symptoms and function in patients with certain severe, disabling circulatory conditions, such as those associated with systemic sclerosis (SSc). It is exclusively an Rx (prescription-only) medication due to its potency and specialized uses.

Iloprost’s Physical Form and General Goal

Iloprost is primarily available as a sterile solution designed for either inhalation via a nebulizer or for intravenous (IV) infusion directly into a vein. It is not available in oral forms. The inhaled form achieves a selective action, directly targeting the blood vessels in the lungs to reduce pressure where it is most needed. This confirms that the inhaled route offers a precise, non-surgical way to affect lung circulation.

The general goal of Iloprost is to promote healthy blood vessel function and improve circulation. By powerfully widening constricted blood vessels and acting as a mild anti-clotting agent, it reduces the resistance to blood flow and helps to ease the workload on the heart, ultimately boosting circulation.

What side effects are possible with Iloprost?

Possible side effects and safety information

The safety profile of Iloprost is characterized by adverse reactions that predominantly reflect its potent action as a Prostacyclin Analog, leading to blood vessel dilation and mild inhibition of platelet aggregation. Regulatory documents classify these effects by frequency and system-organ class.

Reactions categorized as Very Common (geq1/10) include systemic effects of vasodilation such as headache and flushing, as well as local or gastrointestinal reactions like increased cough, nausea, vomiting, and pain in the jaw (trismus). Bleeding events and hypotension are also included in the Very Common frequency classification.

Common (geq1/100 to <1/10) adverse reactions may affect the nervous system (e.g., dizziness, syncope), the cardiovascular system (e.g., tachycardia, palpitations), and the respiratory system (e.g., dyspnea, pharyngolaryngeal pain).

Officially documented Serious Adverse Reactions, though classified as uncommon, include major cardiovascular events such as myocardial infarction and cardiac failure, as well as pulmonary oedema and severe bleeding events. The risk of syncope, often linked to hypotension, is also formally highlighted.

Specific regulatory constraints state that use is restricted in patients with conditions that pose an increased risk of hemorrhage (e.g., active peptic ulcers) and in those with certain unstable cardiovascular conditions (e.g., recent myocardial infarction, decompensated cardiac failure). Furthermore, due to potentially reduced drug elimination, specific safety caution is noted for patients with hepatic dysfunction and for those with renal failure requiring dialysis.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Iloprost is characterized by an exaggeration of its potent vasodilating effect, leading to specific, officially documented clinical manifestations. The prescribing information confirms that cases of overdose generally result from the administration of a supra-therapeutic dose.

Documented Overdose Manifestations

Category	Manifestations (as documented in regulatory sources)
Cardiovascular Effects	Hypotension (low blood pressure), Tachycardia (fast heartbeat), Bradycardia (slow heartbeat)
General Symptoms	Headache, Flushing, Dizziness, Nausea, Vomiting, Diarrhea, Jaw pain, Back pain

Required Emergency Actions

If an overdose is suspected, seek immediate medical attention. Urgent medical care must be sought, particularly if severe signs are present, such as collapse, seizures, trouble breathing, or inability to be awakened. These severe outcomes require prompt intervention and professional monitoring.

Management of Iloprost overdose relies strictly on supportive treatment and symptomatic measures, as official regulatory documentation states that a specific antidote is not known. The mandated initial action is the interruption of the Iloprost administration (inhalation or infusion), followed by monitoring of the patient’s vital signs and clinical status.

Therapeutic Uses of Iloprost

Iloprost: Main Uses and Therapeutic Support

Iloprost is indicated for therapeutic support in several serious medical conditions. In adults, it is approved for the treatment of severe frostbite to assist in reducing the necessity of digit amputations. This provides a treatment option for managing this type of injury, particularly in its advanced stages.

Additionally, Iloprost is used in the management of pulmonary arterial hypertension (PAH), classified as New York Heart Association (NYHA) functional class III. For this patient population, the medication is utilized to support improvements in exercise capacity and to alleviate related symptoms. In certain European regions, an intravenous formulation is authorized for conditions such as thromboangiitis obliterans with ulcers or rest pain, severe inoperable peripheral arterial occlusive disease stages III and IV, and severe Raynaud's phenomenon.

Quick Facts (Therapeutic Domains)

Severe Frostbite: May help reduce the risk of finger or toe amputation in adults.
Pulmonary Arterial Hypertension (PAH): Supports improved exercise capacity and symptom management in class III patients.
Peripheral Vascular Conditions: Authorized in some regions for managing severe peripheral arterial occlusive disease and thromboangiitis obliterans.

Eligibility and Restrictions for Use

Eligibility and Contraindications for Iloprost Use

Official regulatory documents classify patient populations based on eligibility, contraindications, and conditional use for Iloprost. The medicine is primarily approved for use in adults.

Classification	Population/Condition
Absolute Contraindications	Pregnancy, known hypersensitivity to the drug, or conditions with a high risk of haemorrhage (bleeding).
Non-Eligible Conditions	Patients with severe heart failure, a recent myocardial infarction (within 6 months), severe cardiac arrhythmias, or severe uncontrolled hypertension (systolic blood pressure below 85 mmHg).
Age Restriction	Children and adolescents (under 18 years) are not recommended due to insufficient data establishing safety and effectiveness. No routine dose adjustment is specified for older adults based on age alone.
Conditional Use	Patients with hepatic impairment (liver disease) or renal impairment requiring dialysis are eligible, but require a mandatory dose adjustment (extended dosing interval) due to slower drug elimination.
Lactation Status	Breastfeeding is not recommended during treatment.

These constraints establish strict limits on who may safely receive Iloprost, requiring that patients do not present with severe cardiovascular instability or high bleeding risk.

What should I know about interactions with other medicines?

Iloprost Interactions with other medicines and products

The official regulatory profile of Iloprost focuses primarily on two areas of pharmacodynamic reinforcement and strict administration rules.

Interaction Type	Official Regulatory Statement
Pharmacodynamic Potentiation	Co-administration with antihypertensive agents and other vasodilators may lead to increased hypotensive effects. Similarly, combinations with anticoagulants and platelet aggregation inhibitors (e.g., NSAIDs) increase the risk of hemorrhage due to additive antiplatelet effects.
Pharmacokinetic (PK) Findings	No clinically relevant PK/PD interaction has been found with co-medications used for pulmonary arterial hypertension. Iloprost does not affect the pharmacokinetics of co-administered Digoxin, and Acetylsalicylic acid does not alter Iloprost's exposure.

Regulatory Constraints	Official Requirements and Notes
Administration Restrictions	The Iloprost solution for infusion or nebulization must not be mixed with any other medications, solutions, or diluents prior to or during administration.
Population-Specific Note	The elimination is reduced in patients with hepatic dysfunction or renal failure requiring dialysis, which affects overall drug exposure and requires consideration.

The regulatory interaction structure is thus defined by the need to manage the additive effects on blood pressure and clotting, supported by specific procedural constraints that prohibit the mixing of the solution. The profile also officially documents the lack of clinically relevant pharmacokinetic interactions with several common co-medications and notes population-specific pharmacokinetic findings in special populations.

Mechanism of Action

How Iloprost Works

Iloprost's mechanism of action centers on acting as a synthetic analog of prostacyclin (PGI2), engaging systems that modulate vascular tone and platelet aggregation.

Prostanoid Receptor Agonism

This domain covers Iloprost's primary action: binding to and activating the IP (prostacyclin) receptor. This interaction triggers a surge in intracellular cyclic adenosine monophosphate (cAMP), a key second messenger that mediates the drug's downstream effects on vascular and platelet systems.

Vasodilation and Platelet Modulation

As a direct consequence of increased cAMP, Iloprost acts on vascular smooth muscle to induce vasodilation (widening of blood vessels) and exhibits antiplatelet activity. This combination counteracts vessel constriction and inhibits processes driven by platelet activation, resulting in altered blood flow dynamics.

Dosage and Administration Information

How Iloprost is Used: Administration Guidelines

Iloprost is administered via two primary, specialized routes based on the indication: Intravenous (IV) Infusion or Oral Inhalation using a specific nebulizer system. Both routes require adherence to strict dosing schedules and controlled environments.

Administration and Dosing Regimens

Administration Route	Standard Regimen Principle	Frequency and Duration
IV Infusion	Titrated by body weight, starting at 0.5 ng/kg/minute up to a maximum of 2.0 ng/kg/minute.	Administered as a continuous infusion over 6 hours each day. The total treatment course for certain acute conditions (e.g., frostbite) is typically limited to a maximum of 8 consecutive days.
Inhalation	The dose is 5.0 micrograms (mcg) per session, following an initial tolerated dose of 2.5 mcg.	Administered 6 to 9 times daily during waking hours. A minimum interval of at least 2 hours must be observed between administration sessions.

Preparation and Special Conditions

IV Infusion concentrate must be diluted with 0.9% sodium chloride injection prior to use, and the resulting solution must be prepared freshly each day. The IV treatment requires administration under strict monitoring in hospitals or specialized clinics.

Dose Adjustments are mandatory for patients with moderate to severe hepatic impairment or severe renal impairment; the IV dose is initiated at 0.25 ng/kg/minute (half the standard starting dose) or the inhalation interval is increased to 3–4 hours to prevent drug accumulation. The required use of specialized nebulizer devices for inhalation and the necessary hospital setting for infusion define the specific, controlled protocol under which the medicine is used.

Recent Clinical Evidence

Research evidence / Overview of studies for Iloprost

Research evidence for Iloprost is based on different study types tailored to specific severe vascular conditions. The text below describes what the studies evaluated and where limitations exist.

Evidence Overview for Pulmonary Arterial Hypertension (PAH)

Research for inhaled Iloprost was studied for use in adults diagnosed with PAH, a condition marked by functional limitations. Evidence primarily comes from short-term, randomized controlled trials (RCTs) that compared Iloprost against a placebo. Studies were designed to evaluate outcomes related to functional capacity, specifically measuring the 6-Minute Walk Distance (6MWD), and to track clinical worsening. Studies reported measurements for functional capacity observed during the study period. While functional outcomes were evaluated in controlled settings, the follow-up durations were limited (around 12 weeks) in these key RCTs. Long-term effects are primarily characterized by less controlled observational studies.

Evidence for Severe Frostbite and Other Severe Vascular Conditions

For Severe Frostbite, the evidence base is more limited, relying mainly on a single controlled trial with a modest sample size. Research examined outcomes related to tissue preservation, specifically tracking the frequency of digit amputation. Data show patterns related to this predictive measure and the final surgical outcome in the studied populations. Certainty remains low because the findings primarily apply only to the specific, small population studied within the initial period following the injury.

Other severe vascular conditions—including advanced Peripheral Arterial Occlusive Disease (PAOD) and severe Raynaud's phenomenon—have been explored through a mix of RCTs and retrospective observational analyses. Studies monitored outcomes linked to inflammatory states, such as the healing of chronic ulcers and relief from ischemic rest pain. Research reports that findings for these patient-reported outcomes were mixed, and evidence quality varies across studies, meaning definitive conclusions about long-term impact are not fully established. Data for certain groups, such as pediatric or older adults with comorbidities, remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Iloprost (FAQ)

Q: Is Iloprost used for conditions other than PAH?

Yes, official approvals include its use for severe frostbite when administered via IV infusion. In addition to its primary use for Pulmonary Arterial Hypertension (PAH), research has also examined its role in other severe vascular conditions, such as Raynaud's phenomenon.

Q: How long do the effects of Iloprost last after administration?

Regulatory information indicates that the drug has a relatively short half-life, meaning it is quickly processed by the body. The half-life is reported to be between 20 and 30 minutes. Following an inhalation session, the drug is generally not detectable in the bloodstream within an hour.

Q: Are there any common foods or drinks that interact with Iloprost?

According to the official product information, there are no known interactions between Iloprost and common foods or drinks. However, due to the drug’s potential to lower blood pressure, combining it with substances like alcohol may increase the reported risk of effects such as dizziness.

Q: What are the most common things people feel when they start taking Iloprost?

Many of the most frequent reactions reported upon starting treatment are related to the drug's action of widening blood vessels (vasodilation). These commonly include a headache, a feeling of flushing or warmth, nausea, and pain or stiffness in the jaw or tongue.

Q: What should I know about taking pain relievers while using Iloprost?

Official regulatory documents caution that taking Iloprost alongside other antiplatelet drugs, such as non-steroidal anti-inflammatory medicines (NSAIDs), may increase the risk of bleeding. This is due to their combined anti-clotting effects.

Q: Is it normal to feel dizzy during or after the infusion?

Dizziness and syncope (fainting) are listed in official documents as Common adverse reactions. These effects are often linked to the drug's effect of lowering blood pressure. Regulatory instructions suggest bearing in mind the possibility of low blood pressure when changing position after administration.

Q: Are there any restrictions on activity while on Iloprost treatment?

Official warnings state that patients should not drive a car or operate any tools or machines if they experience dizziness or fainting (passing out). This caution is tied to the potential for low blood pressure, which can impair alertness and coordination.

Q: Do researchers know if Iloprost helps with Raynaud's Phenomenon?

Yes, research evidence includes controlled trials examining intravenous Iloprost for Raynaud's phenomenon in patients with systemic sclerosis. Studies have evaluated outcomes such as attack frequency and severity and reported observations of reduced severity and frequency in the studied populations.

Q: What happens if a dose of Iloprost is missed?

Regulatory guidance for the inhaled form states that if a treatment session is missed, therapy should be resumed as soon as possible at the usual dose. Official regulatory guidance states that double doses should not be taken to make up for a missed session.

Q: Does Iloprost have known interactions with common supplements like vitamins?

Regulatory resources advise patients to discuss the use of all over-the-counter (OTC) medicines, vitamins, and supplements with their healthcare provider. Potential interactions have been reported for some supplements, so a review of all products is necessary.

Q: Is Iloprost approved in all countries for the same uses?

No, approvals for the drug, including its approved routes of administration (inhalation versus infusion) and specific indications, may vary between different countries and regulatory bodies, such as in the USA compared to parts of Europe.

Q: What should people avoid doing right before or after the Iloprost infusion?

The prepared infusion solution must not be mixed with any other medicines or diluents. Immediately after the administration, patients should be mindful of the possibility of low blood pressure, particularly when moving from a lying to an upright position.

Q: Is there a generic version of Iloprost available?

According to the latest regulatory data on patents and exclusivity, there is no FDA-approved generic version of the inhaled or intravenous forms of the drug currently available in the United States, due to active patents and regulatory exclusivities.

Q: What are the general expectations about the research on Iloprost for certain vascular conditions?

Research has evaluated outcomes such as functional capacity (e.g., 6-Minute Walk Distance) for PAH patients. Clinical trials for severe frostbite have observed patterns related to a reduction in amputation rates in the studied populations.

Q: What is the official research focus on Iloprost beyond its primary indication?

Official research has focused on its approved uses, including its effect on functional capacity for Pulmonary Arterial Hypertension and its role in reducing the risk of amputation in severe frostbite. Other studies have examined its use in Raynaud's phenomenon secondary to systemic sclerosis.

Q: Does Iloprost cause headaches, and if so, how is this generally managed?

Headache is classified as a Very Common side effect, as a consequence of the drug's vasodilating action. If the headache is severe during administration, official instructions recommend that the infusion rate should be reduced until a tolerated dose is found.

Q: What are the general criteria used by doctors to determine eligibility for Iloprost?

Eligibility is based on regulatory approval for specific severe conditions, such as Pulmonary Arterial Hypertension (PAH) and severe frostbite. For PAH, clinical trials focused on patients with advanced functional limitations, typically those in NYHA Functional Class III or IV.

Q: Can Iloprost interact with aspirin or other antiplatelet drugs?

Yes, co-administration with aspirin (Acetylsalicylic Acid) can increase the risk of bleeding due to the combined effects of both drugs on platelet function. Official guidance recommends caution when these types of medicines are used together.

Q: How quickly does Iloprost start working?

Official patient information notes that some patients may experience the onset of effects at once, such as feeling warmth in cold extremities. However, the full scope of observed effects may take several days or weeks to develop.

How should Iloprost be stored and disposed of?

Storage and Disposal Requirements for Iloprost

Storage Conditions for Unopened Product

The medicine must be stored in its closed, original container and protected from excess heat, moisture, and direct light. The product must be strictly protected from freezing. Iloprost inhalation solution requires storage at room temperature (20 C to 25 C). The infusion concentrate may have no specific temperature requirement for the unopened package.

Stability and Handling

Product State	Stability Requirement
Inhalation Solution	Discard any solution remaining in the nebulizer after each dose.
Diluted Infusion	Must be used immediately or stored for a maximum of 24 hours under refrigeration (2 C to 8 C).

The medicine must be kept out of the sight and reach of children.

Disposal Protocol

Any unused medicine or waste material must be disposed of in accordance with local requirements. Prior to disposal, it is recommended to scratch out all identifying information from the prescription label.

Iloprost